Results 81 to 90 of about 4,340 (195)
Profile of belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma
OncoTargets and Therapy, 2014 The peripheral T-cell lymphomas are a rare and heterogeneous group of mature T-cell lymphomas with limited available therapies. The outcome of frontline chemotherapy regimens has been disappointing, with a long-term survival of only 20%-30%. There is an urgent need to optimize induction therapy by incorporating novel agents that target the dysregulated
Bodiford,Andrew +3 more
openaire +4 more sources
Single‐cell analysis reveals neuroprotective histone deacetylase inhibitor pathways
Alzheimer's &Dementia, Volume 22, Issue 2, February 2026.Abstract INTRODUCTION Alzheimer's disease (AD) involves β‐amyloid (Aβ) accumulation, tau pathology, and neuroinflammation, driving cognitive decline. Despite extensive research, disease‐modifying therapies remain elusive. We integrated single‐cell RNA sequencing (scRNA‐seq), spatial transcriptomics, and in vitro validation to identify repurposable ...
Madeline Peyton +12 more
wiley +1 more source
Histone Deacetylase Inhibitors Are Protective in Acute but Not in Chronic Models of Ototoxicity
Frontiers in Cellular Neuroscience, 2017 Previous studies have reported that modification of histones alters aminoglycoside-induced hair cell death and hearing loss. In this study, we investigated three FDA-approved histone deacetylase (HDAC) inhibitors (vorinostat/SAHA, belinostat, and ...
Chao-Hui Yang +6 more
doaj +1 more source
Artificial Cells, Nanomedicine, and Biotechnology, 2019 We, the Editors and Publisher of the journal Artificial Cells, Nanomedicine, and Biotechnology, have retracted the following article:Pengwei Lu, Yuanting Gu, Lin Li, Fang Wang, Xue Yang & Yunqing Yang (2019) Belinostat suppresses cell proliferation by ...
Pengwei Lu +5 more
doaj +1 more source
, 2013 Panel A. Effect of conditioned medium from Belinostat pre-exposed cells on activation of the Hippo reporter in naïve cells (not previously exposed to the drug).
Miguel Reyes-Múgica (5654968) +2 more
core +1 more source
, 2018 Prostate cancer as the second most prevalent cancer and the sixth most common cause of cancer death among men appears with increasing mortality incidence rate amongst Asian population.
Nikbakht-Dastjerdi, Mehdi +3 more
core +1 more source
Tạp chí Khoa học Đại học Cần Thơ, 2020 Belinostat là thuốc có khả năng ức chế enzyme HDAC khá tốt, được sử dụng điều trị các khối u ác tính về huyết học và khối u rắn. Trong nghiên cứu này, các dẫn xuất tương tự belinostat đã được tổng hợp thành công qua quy trình đơn giản và hiệu quả, phù ...
Nguyễn Cường Quốc +12 more
doaj
Novel and Future Therapeutic Drugs for Advanced Mycosis Fungoides and Sézary Syndrome
Frontiers in Medicine, 2019 Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes of cutaneous T-cell lymphoma. The majority of MF cases present with only patches and plaques and the lesions are usually limited to the skin.
Tomonori Oka, Tomomitsu Miyagaki
doaj +1 more source
Pharmacokinetic parameters for belinostat after 30 min i.v. infusion in Phase I trial.
, 2013 Abbreviation: Cmax, maximum concentration; Tmax, time to maximum concentration; AUC0–24 h, area under the curve from 0 to 24 h; T1/2, half-life at the elimination phase; CL, clearance; Vz, volume of distribution.
Win-Lwin Thuya (277890) +16 more
core +1 more source
New developments in the treatment of peripheral T-cell lymphoma – role of Belinostat
Cancer Management and Research, 2015 Peter Reimer Clinic for Hematology, Medical Oncology and Stem Cell Transplantation, Evangelisches Krankenhaus Essen-Werden gGmbH, Essen, Germany Abstract: Peripheral T-cell lymphomas (PTCL) represent a heterogeneous group of rare malignancies that with ...
Reimer P
doaj